Midcareer Development Award in Neuroaging and Geriatric Pharmacoepidemiology Research

神经衰老和老年药物流行病学研究职业中期发展奖

• 批准号: 10351611
• 负责人: Allison Willis
• 金额: $ 16.32万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10351611
• 关键词: Address; Advisory Committees; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Anti-Cholinergics; Award; Basic Science; Biological; Biometry; Caliber; Caring; Chronic; Clinical; Coupled; Data Analyses; Data Collection; Data Set; Dementia; Dementia with Lewy Bodies; Development; Discipline; Disease; Drug Exposure; Drug Interactions; Drug Prescriptions; Educational Background; Elderly; Electronic Health Record; Environment; Epidemiology; Epilepsy; Evaluation; Event; Exposure to; Funding; Geriatrics; Goals; Guidelines; Health; Health Disparities Research; Health Services; Health Services Research; Health system; Huntington Disease; Impaired cognition; Individual; Informatics; Infrastructure; Intellectual functioning disability; International; Investigation; Knowledge; Learning; Lewy Body Dementia; Link; Medical; Medicare claim; Mentors; Mentorship; Methodology; Mid-Career Clinical Scientist Award (K24); Minority; Modeling; Monitor; Motor; Multiple Sclerosis; Neighborhoods; Neurologic; Neurologic Dysfunctions; Neurologist; Neurology; Observational Study; Outcome; Parkinson Disease; Parkinson' s Dementia; Patients; Pennsylvania; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacology; Pharmacotherapy; Population; Process; Psychiatry; Public Health; Quality of Care; Reporting; Research; Research Design; Research Infrastructure; Research Methodology; Research Personnel; Research Training; Risk; Role; Safety; Sampling; System; Time; Training; Training Programs; Traumatic Brain Injury; Treatment outcome; Universities; analytic epidemiology; care delivery; care outcomes; career; chronic neurologic disease; clinical care; clinical practice; cognitive function; collaborative environment; dementia risk; design; drug development; epidemiology study; evidence base; health care disparity; health care service utilization; health disparity; health equity; health service use; high risk; improved; innovation; insight; medical specialties; mild cognitive impairment; mixed dementia; multidisciplinary; neighborhood disadvantage; nervous system disorder; next generation; novel; patient oriented; patient oriented research; programs; prospective; recruit; research and development; social factors; success; treatment adherence

Dr. Willis is a neurologist, neuroepidemiologist, and health services researcher who has established a nationally- and internationally- recognized, independently funded research program committed to patient-oriented research focused on drug effects, care process and outcome disparities, and health service use in older adults with neurological disease. She has a successful record in mentoring trainees who approach POR from multiple educational backgrounds. Proposal aims: (1) to conduct analytical epidemiology research examining the impact of prescribing practices, drug exposures, drug-drug and drug-disease interactions on clinical, patient-reported and health care utilization outcomes in older adults, particularly those with Parkinson Disease + Dementia; Dementia with Lewy Bodies (which together comprise Lewy Body Dementia, an Alzheimer’s Disease Related Dementia/ADRD), Alzheimer’s disease (AD), Mild cognitive impairment and chronic neurological disease; (2) to conduct health disparities and health services research in older adults with neurological disease, particularly those with the above ADRDs and AD, to gain actionable insights into systematic barriers to equal care; (3a) to develop new studies at the intersection of aging, neurology, and pharmacoepidemiology focused on the biological, clinical, and qualitative effects of deprescribing and safety-guided CNS drug prescribing on cognitive function and cognitive decline in individuals with the above ADRDs, AD, and MCI; (3b) to develop new studies at the intersection of aging, disparities, and health services research, focused on describing and decomposing the relative contributions of individual, neighborhood, and social factors on disparities in guideline adherent treatment initiation, escalation, and monitoring; treatment adherence and outcomes in older adults with neurological disease, including ADRDs and AD; (4) to use Dr. Willis’s research program to train and mentor new investigators in research methods that will improve health care outcomes for older adults with ADRDs, AD and chronic neurological disorders through neuroprotective prescribing, more effective and equitable care delivery. A K24 award will provide Dr. Willis with the protected time needed to develop new research focused on neuroprotective prescribing and health disparities, generate knowledge on the drivers and effects of medical care and drug therapies for neurological disorders. A K24 will also allow Dr. Willis to increase her mentoring expertise and develop a formal mentoring program for engaging young investigators drawn from neurology, epidemiology, geriatrics, psychiatry, pharmacology, informatics, and biostatistics. Dr. Willis’s mentoring program will (1) provide mentees with direct exposure to primary data collection and secondary data analysis (2) create an interdisciplinary environment where trainees from a range of specialties will learn directly from each other (3) provide mentees with individualized research and career mentoring from her. The outstanding institutional environment and the K24 Advisory Team Dr. Willis has assembled to monitor and guide her progress at the University of Pennsylvania support the success of this proposal.

Willis 博士是一位神经学家、神经流行病学家和卫生服务研究员，他建立了一个国内和国际认可的、独立资助的研究项目，致力于以患者为导向的研究，重点关注患有神经系统疾病的老年人的药物作用、护理过程和结果差异以及卫生服务的使用。她在指导具有多种教育背景的 POR 学员方面拥有成功的记录。提案旨在：(1) 开展分析流行病学研究，检查处方实践、药物暴露、药物与药物以及药物与疾病之间的相互作用对老年人（特别是患有帕金森病+痴呆症的老年人）的临床、患者报告和医疗保健利用结果的影响；路易体痴呆（包括路易体痴呆、阿尔茨海默病相关痴呆/ADRD）、阿尔茨海默病 (AD)、轻度认知障碍和慢性神经系统疾病； (2) 对患有神经系统疾病的老年人，特别是患有上述 ADRD 和 AD 的老年人进行健康差异和卫生服务研究，以获得关于平等护理的系统性障碍的可行见解； (3a) 在衰老、神经病学和药物流行病学的交叉领域开展新的研究，重点关注停用和安全指导的 CNS 药物处方对患有上述 ADRD、AD 和 MCI 的个体认知功能和认知衰退的生物学、临床和定性影响； (3b) 在老龄化、差异和卫生服务研究的交叉领域开展新的研究，重点是描述和分解个人、邻里和社会因素对指南依从性治疗启动、升级和监测差异的相对贡献；患有神经系统疾病（包括 ADRD 和 AD）的老年人的治疗依从性和结果； (4) 利用 Willis 博士的研究计划来培训和指导新研究人员的研究方法，通过神经保护性处方、更有效和公平的护理服务，改善患有 ADRD、AD 和慢性神经系统疾病的老年人的医疗保健结果。 K24 奖项将为 Willis 博士提供所需的受保护时间，以开发专注于神经保护处方和健康差异的新研究，并产生有关神经系统疾病的医疗护理和药物治疗的驱动因素和影响的知识。 K24 还将使 Willis 博士能够提高她的指导专业知识，并制定正式的指导计划，以吸引来自神经病学、流行病学、老年病学、精神病学、药理学、信息学和生物统计学的年轻研究人员。威利斯博士的指导计划将 (1) 为学员​​提供直接接触主要数据收集和二次数据分析的机会 (2) 创建一个跨学科的环境，让来自不同专业的学员可以直接相互学习 (3) 为学员​​提供个性化的研究和她的职业指导。 Willis 博士在宾夕法尼亚大学组建的出色的制度环境和 K24 顾问团队来监督和指导她的进步，为这一提案的成功提供了支持。